Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02375984 · ClinicalTrials.gov registry record · Phase 2
A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas
A Phase 2 study, sponsored by Saint John's Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02375984 is a Phase 2 study that was terminated before completion, run by Saint John's Cancer Institute. The registered enrollment target is 1 participants.
The verdict
NCT02375984, a Phase 2 study, was terminated before completion, sponsored by Saint John's Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this protocol is to determine whether autologous TIL infused in conjunction with systemic high-dose IL-2 after non-myeloablative chemotherapy with cyclophosphamide and fludarabine can cause consistent and durable objective responses in patients who have metastatic melanoma at the John Wayne Cancer Institute (JWCI).
Interventions
- BIOLOGICAL Tumor Infiltrating Lymphocytes (TIL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-03-16 |
| Est. Completion | 2017-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02375984
The ClinicalTrials.gov registry entry for NCT02375984 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint John's Cancer Institute, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tumor Infiltrating Lymphocytes (TIL) is the first listed.
NCT02375984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02375984 about?
NCT02375984 is a clinical study titled "A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas". The purpose of this protocol is to determine whether autologous TIL infused in conjunction with systemic high-dose IL-2 after non-myeloablative chemotherapy with cyclophosphamide and fludarabine can cause consistent and durable objective responses in patients who have metastatic melanoma at the John...
What is the current status of trial NCT02375984?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-03-16. Estimated completion is 2017-06-01.
What interventions are being tested in trial NCT02375984?
The interventions under investigation include: Tumor Infiltrating Lymphocytes (TIL) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02375984?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.